Adicet Bio, Inc. (1IJA.F)
| Previous close | 1.2850 |
| Open | 1.5480 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 1.5480 - 1.5480 |
| 52-week range | 0.9156 - 6.8040 |
| Volume | |
| Avg. volume | 71 |
| Market cap | 155.507M |
| Beta (5Y monthly) | 1.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.0800 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 28.29 |
Business WireAdicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
REDWOOD CITY, Calif. & BOSTON, May 07, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 2024 Citizens JMP Life Sciences Conference being held from May 13-14, 2024 in New York.
Business WireAdicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif. & BOSTON, April 30, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on April 30, 2024.
Business WireAdicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
REDWOOD CITY, Calif. & BOSTON, April 22, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that an abstract featuring new preclinical data highlighting ADI-270, an armored allogeneic "off-the-shelf" gamma delta CAR (chimeric antigen receptor) T cell therapy candidate targeting CD70 positive cancers, has been selected for an oral presentation at the AS
